欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - carglumic acid - amino acid metabolism, inborn errors; propionic acidemia - other alimentary tract and metabolism products, - carbaglu is indicated in treatment of:hyperammonaemia due to n-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - betaine anhydrous - homocystinuria - other alimentary tract and metabolism products, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl).cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.

欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - mercaptamine hydrochloride - cystinosis - ophthalmologicals - cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.

欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - mercaptamine bitartrate - cystinosis - other alimentary tract and metabolism products, - cystagon is indicated for the treatment of proven nephropathic cystinosis. cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - tocofersolan - cholestasis; vitamin e deficiency - vitamins - vedrop is indicated in vitamin-e deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.

欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - zinc - hepatolenticular degeneration - other alimentary tract and metabolism products, - treatment of wilson's disease.

欧州連合 - 英語 - EMA (European Medicines Agency)

recordati rare diseases - ibuprofen - ductus arteriosus, patent - cardiac therapy - treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 82.26 mg (equivalent: pasireotide, qty 60 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 54.84 mg (equivalent: pasireotide, qty 40 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - pasireotide embonate, quantity: 27.42 mg (equivalent: pasireotide, qty 20 mg) - injection, modified release - excipient ingredients: polyglactin glucose; polyglactin - signifor lar is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative or who are inadequately controlled on treatment with other somatostatin analogues.